SMAD3 and hepatocellular carcinoma: Another study demonstrated that PP2A inhibition by LB-100 sensitized hepatocellular carcinoma cells for treatment with the licensed anti-cancer drug sorafenib by inducing a hyper-phosphorylation of SMAD3 (mothers against decapentaplegic homolog 3), which, in turn, leads to the downregulation of B-cell lymphoma 2 (Bcl-2) resulting in the induction of apoptosis [41].